The Ellis Martin Report Stock Market Press Releases and Company Profile

View in Other Languages MONEY TALK RADIO with XORTX Therapeutics Inc. (NASDAQ:XRTX) Dr. Allen Davidoff Explains Advanced Drug Therapy for Kidney Disease and Diabetes MONEY TALK RADIO mit XORTX Therapeutics Inc. (NASDAQ:XRTX) Dr. Allen Davidoff erklärt fortschrittliche medikamentöse Therapie bei Nierenerkrankungen und Diabetes XORTX Therapeutics Inc.(NASDAQ:XRTX)的 MONEY TALK RADIO 艾伦·大卫杜夫 (Allen Davidoff) 博士解释了肾脏疾病和糖尿病的先进药物治疗 MONEY TALK RADIO con XORTX Therapeutics Inc. (NASDAQ:XRTX) El Dr. Allen Davidoff explica la terapia farmacológica avanzada para la enfermedad renal y la diabetes 

Malibu, CA, Mar 3, 2024 AEST (ABN Newswire) - This is Money Talk Radio with Ellis Martin. Today we're going to take a deep dive into a publicly traded NASDAQ company developing innovative therapies to improve the quality of life of patients with progressive kidney disease as well as diabetes. The company is XORTX Therapeutics Inc. (googlechartNASDAQ:XRTX)(googlechartCVE:XRTX) a late-stage clinical pharmaceutical company. We'll speak with Dr. Allen Davidoff. We urge you to pay attention to this dissertation, noting the revolutionary therapy being developed AND the potential investment opportunity therewithin.

XORTX Therapeutics is a paid sponsor of Money Talk Radio.

To Listen to the Interview, please visit:

About The Ellis Martin Report

Ellis Martin ReportThe Ellis Martin Report (TEMR) is an internet based radio program showcasing potentially undervalued companies to an audience of potential retail investors and fund managers that comprise our listening audience. TEMR is broadcasted on the VoiceAmerica Business Channel and The Opportunity Radio Network. CEO and company interviews are paid for by those represented on the program. 

About XORTX Therapeutics, Inc.

XORTX Therapeutics, Inc. (NASDAQ:XRTX) (CVE:XRTX) is a drug based biotechnology company primarily focused on orphan disease indications which have aberrant purine metabolism and frequently high serum uric acid imbalance. Our focus on developing kidney therapies also includes therapeutics programs for large markets such as diabetic nephropathy and acute kidney injury associated with respiratory virus infections such as SARS-CoV-2.

We possess patents and patent applications that may include U.S. and international rights regarding the development of uric acid-lowering agents for the treatment of hypertension, insulin resistance, diabetes, metabolic syndrome, and kidney injury. 


T: +1-403-455-7727

ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 133) (Last 30 Days: 555) (Since Published: 2654) 

View in Other Languages 2654562444421 (4081)